May 17, 2020

TiGenix looks into drug partnering

2 min
TiGenix looks into drug partnering.jpg
Written by Alyssa Clark The Brussels based company TiGenix is looking to sell its Dutch drug manufacturing facility located in Sittard-Green, and part...

Written by Alyssa Clark


The Brussels based company TiGenix is looking to sell its Dutch drug manufacturing facility located in Sittard-Green, and partner with a new company for its candidate treatment for a special disorder known to link to Crohn’s disease. TiGenix was pleased with the Dutch authorities, after they gave their permission to allow the company to continue to sell the facility, while still manufacturing its product during the selling process.

Advanced conversations are underway between TiGenix and a number of interested potential partners, over commercial rights to the Cx601 outside of Europe. U.S health regulators are also joining in on this conversation, in hopes of getting a trial run of the drug in the U.S. in the near future. Most recently, TiGenix has enrolled patients for their Phase III level of treatment. The trials or Cx601 are for the treatment of complex perianal fistulas, abnormal channels that can develop between the end of the bowel and the skin, which frequently occurs in the bowels’ of patients with Crohn’s disease.

TiGenix’s main drug ChrondoCelect (which repairs damaged cartilage in the knee) has risen by 21 percent in this quarterly trading period, in just the first nine months of 2013 alone. The company projects more than a 20 percent rise in the next full-year sales, already earning the company $4.2 million.

Driven by increased sales in the Netherlands and Belgium, TiGenix believes their products will branch into mainstream Spain and Britain by 2014.


About the Author

Alyssa Clark is the Editor of Healthcare Global

Share article

May 12, 2021

OMNI: First-ever platform to launch citizen RPA developers

3 min
OMNI is empowering employees to become ‘citizen RPA developers’, democratising automation and other AI technologies

Robotic process automation (RPA) is the fastest growing segment of the enterprise software market due to its many benefits - from reducing manual errors to processing tasks faster. For businesses to truly benefit from this technology, RPA needs democratisation, and this is where citizen RPA development comes in. 

Gartner describes a citizen RPA developer as "a user who creates new business applications for consumption by others using development and runtime environments sanctioned by corporate IT.” This could be anyone using IT tools and technology, not limited to IT specialists. 

The work citizen RPA developers do spans from identifying automation opportunities to developing RPA architecture and solution proposals, focusing on scalability and extensibility. By deploying citizen RPA developers, organisations can enable enterprise automation and digital transformation on a much larger scale. 

This is particularly beneficial for businesses struggling to undertake digital transformation, as a citizen RPA development programme can help drive adoption of automation as a strategic growth driver at multiple levels. With increased adoption, the cost of digital transformation becomes lower, increasing RoI. 

Technology needs to be democratised – right from low-code and no-code platforms, business process modelling and identifying automation opportunities to decision-makers at all levels, creating a pool of early adopters. This group could comprise people across different functions, especially those who are aware of customer preferences, industry trends and end user experience.

But how can organisations harness the power of citizen RPA development? Step forward AiRo Digital Labs, a Chicago-headquartered global tech company. 

AiRo provides innovative digital and automation solutions for the healthcare, pharmaceutical and life sciences sectors. In 2021 they launched OMNI, a subscription-based, SaaS platform to help clients accelerate their citizen RPA developer program and build digital centres of excellence (COE) within their organisation. 

OMNI provides a personal RPA coach and virtual digital playground that helps enterprises rapidly build and scale automation, removing the risk of failure or talent gaps. The latter is key as research has shown that digitalisation is far more successful when championed by internal employees. 

This has the added bonus of empowering employees - who will self-learn technologies including robotic process automation (RPA), artificial intelligence, machine learning, chatbots, and natural language processing (NLP), reducing the lead time for new applications and technology, as well as reducing technical gaps, making up for skills shortages and enabling their business to respond faster to critical market challenges. The virtual sandbox within OMNI gives access to all the major intelligent automation platforms where citizen RPA developers can build DIY digital prototypes. Additionally, they can access more than 150 digital assets within OMNI marketplace. 

The platinum helpdesk of OMNI acts as your personal coach and is available 24 x 7 to address issues during the digital learning, prototype building, and digital governance journey.  

Another key benefit is that it enables digitalisation to be bespoke to each organisation, compared to off-the-shelves initiatives plugged into the enterprise. Individual organisation's objectives decide the scope and size of the process. 

As Gartner state, in today’s world of SaaS, cloud, low-code and “no-code” tools, everyone can be a developer. 

Share article